Diabetic gastric palsy: FDA approves peoxychloramine nasal spray Gimoti on the market

Evoke Pharma announced thatFDAapproved the application of the peoxychloramine nasal spray Gimoti, making it the first drug administered by nasal administration to relieve acute and recurrentdiabetesadult patients with gastric palsyGimoti is a nasal spray for metachloramine, which can be used as an alternative to oral and injectable administrationTheblood vessels in the epithelial cell layer of the mucous membrane of the nasal cavity are rich in, which can deliver methoxychloramine molecules directly to the whole bodyAdministration in this way does not need to be metabolized through the liver, thus increasing the utilization of the drugDavid Gonyer, chief executive of, said: "Most patients are unable to adequately alleviate the symptoms of gastric palsy from current treatments and we are pleased to offer unique non-oral treatment options"
FDA rejected Evoke's application in April last year on the grounds of clinical pharmacology and quality-related issues, and the company resubmitted the application in December, providing patient use and experience data for clinical trials, as well as an analysis of pump performance characteristics for products and commercial-scale registered batches used in bioavailability studiesdiabetic gastric palsy is a common complication of diabetes, characterized by gastric dysfunction and delayed gastric emptying, characterized by bloating, anorexia, nausea and vomiting